LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

30-Second Coronavirus Test Returns Results as Accurately and Sensitively as PCR Test

By LabMedica International staff writers
Posted on 08 Apr 2022
Print article
Image: The motherboard of a new COVID-19 rapid testing device (Photo courtesy of University of Florida)
Image: The motherboard of a new COVID-19 rapid testing device (Photo courtesy of University of Florida)

With any highly infectious disease, time can be a killer. It is crucial to get a test result for a pathogen quickly, lest someone continue in their daily lives infecting others. And delays in testing have undoubtedly exacerbated the COVID-19 pandemic. Unfortunately, the most accurate COVID-19 test often takes 24 hours or longer to return results from a lab. At-home test kits offer results in minutes but are far less accurate or sensitive. Researchers have now developed a COVID-19 testing device that can detect coronavirus infection in as little as 30 seconds as sensitively and accurately as a PCR, or polymerase chain reaction test, the gold standard of testing.

Researchers at the University of Florida (Gainesville, FL, USA) in association with scientists at National Yang Ming Chiao Tung University (Taipei, Taiwan) have developed the device that could transform public health officials’ ability to quickly detect and respond to the coronavirus - or the next pandemic. Like PCR tests, the device is 90% accurate with the same sensitivity, according to a recent peer-reviewed study.

The hand-held apparatus is powered by a 9-volt battery and uses an inexpensive test strip, similar to those used in blood glucose meters, with coronavirus antibodies attached to a gold-plated film at its tip. The strip is placed on the tongue to collect a tiny saliva sample. The strip is then inserted into a reader connected to a circuit board with the brains of the device. If someone is infected, the coronavirus in the saliva binds with the antibodies and begins a dance of sorts as they are prodded by two electrical pulses processed by a special transistor. A higher concentration of coronavirus changes the electrical conductance of the sample. That, in turn, alters the voltage of the electrical pulses.

The voltage signal is amplified a million times and converted to a numerical value - in a sense, the sample’s electrochemical fingerprint. That value will indicate a positive or negative result, and the lower the value, the higher the viral load. The device’s ability to quantify viral and antibody load makes it especially useful for clinical purposes, according to the researchers. The product can be constructed for less than USD 50 in contrast to PCR test equipment which can cost thousands.

Several institutions have worked on devices using a field effect transistor, or FET, like that found in the COVID-19 testing device which the researchers are developing. But those devices are basically one-offs - a sample is applied directly to the FET, which means the transistor is not reusable and must be discarded. That makes those devices expensive and impractical for mass testing. Then the researchers hit upon on the idea of separating the transistor from the sample, like blood glucose meters that use test strips to collect a drop of blood after a lancet pierces a finger. This innovation makes the device unique, affordable and easy to use. The device could be used for venues with large crowds, such as concerts, sporting events, classrooms, in addition to medical settings. The unit would also provide access to accurate, inexpensive testing in rural areas or in developing nations and offers limitless options for personal uses.

The device is not yet approved by the U.S. Food and Drug Administration. First, the researchers will have to ensure that test results are not thrown off by cross-contamination with other pathogens that might be found in the mouth and saliva. These include other coronaviruses, staph infections, the flu, pneumonia and 20 others. The research team is also studying its ability to detect specific proteins that could be used to diagnose other illnesses, including cancer, a heart attack and immune health.

“There is nothing available like it,” said Josephine Esquivel-Upshaw, D.M.D., a professor in the UF College of Dentistry’s department of restorative dental sciences and member of the research team that developed the device. “It’s true point of care. It’s access to care. We think it will revolutionize diagnostics.”

Related Links:
University of Florida
National Yang Ming Chiao Tung University 

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.